Европска Унија - Шведски - EMA (European Medicines Agency)

krka, d.d., novo mesto  - telmisartan - hypertension - angiotensin ii-antagonister, vanliga - hypertensiontreatment av essentiell hypertoni hos vuxna. hjärt-preventionreduction av kardiovaskulär sjuklighet hos patienter med manifest atherothrombotic hjärt-och kärlsjukdomar (historia av hjärtinfarkt eller perifer arteriell sjukdom), eller typ 2-diabetes mellitus med dokumenterade mål organskador.

Европска Унија - Шведски - EMA (European Medicines Agency)

bayer ag  - vardenafil - erektil dysfunktion - urologiska - behandling av erektil dysfunktion hos vuxna män. erektil dysfunktion är oförmågan att uppnå eller behålla en penile erektion som är tillräcklig för tillfredsställande sexuell prestanda. för att vivanza att vara effektiv, att en sexuell stimulering krävs. vivanza är inte avsett för användning av kvinnor.

Европска Унија - Шведски - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 och 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Европска Унија - Шведски - EMA (European Medicines Agency)

ucb pharma s.a. - romosozumab - osteoporos - läkemedel för behandling av bensjukdomar - evenity är indicerat för behandling av svår osteoporos hos postmenopausala kvinnor med hög risk för fraktur.

Европска Унија - Шведски - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - solriamfetol hydroklorid - narcolepsy; sleep apnea, obstructive - psychoanaleptics, - sunosi är indicerat för att förbättra vakenhet och minska överdriven sömnighet under dagtid hos vuxna patienter med narkolepsi med eller utan kataplexi). sunosi är indicerat för att förbättra vakenhet och minska överdriven sömnighet under dagtid (eds) hos vuxna patienter med obstruktiv sömnapné (osa) vars eds har inte varit tillfredsställande behandlas med primär osa behandling, såsom continuous positive airway pressure (cpap).

Европска Унија - Шведски - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Европска Унија - Шведски - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Европска Унија - Шведски - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomyom - hypofysiska och hypotalamiska hormoner och analoger - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

fresenius kabi ab - glukosmonohydrat; kalciumkloriddihydrat; kaliumklorid; magnesiumkloridhexahydrat; natriumacetattrihydrat; natriumklorid - infusionsvätska, lösning - glukosmonohydrat 11 mg aktiv substans; natriumacetattrihydrat 4,082 mg aktiv substans; kalciumkloriddihydrat 0,147 mg aktiv substans; kaliumklorid 0,298 mg aktiv substans; natriumklorid 6,429 mg aktiv substans; magnesiumkloridhexahydrat 0,203 mg aktiv substans

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

teva sweden ab - remifentanilhydroklorid - pulver till koncentrat till injektions-/infusionsvätska, lösning - 1 mg - remifentanilhydroklorid 1,1 mg aktiv substans - remifentanil